Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Axonyx cleared to initiate phase I clinical trials of phenserine

Nov. 4, 1999

FDA requests further data to support frovatriptan NDA

Nov. 3, 1999

Relpax is approvable, FDA says

Nov. 3, 1999

CRF antagonists under study at DuPont for anxiety, depression, etc.

Nov. 3, 1999

AHP describes novel serotonergic agents for depression and anxiety

Nov. 2, 1999

Merz concludes two phase III trials of memantine in vascular dementia

Nov. 2, 1999

Novel class of Ampakines described by U.S. university researchers

Nov. 2, 1999

Guilford claims new NAALADase inhibitors for glutamate abnormalities, prostate disorders

Nov. 2, 1999

First once-daily morphine approved in Japan

Nov. 2, 1999

Naturally occurring antiapoptotic compounds disclosed by Shionogi

Nov. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...